News

NANBIOSIS participation in CPhI Worldwide

NANBIOSIS has participated in the most important event of the pharmaceutical industry, CPhI Worldwide, the largest fair held in Spain. More than 45,000 professionals from more than 150 countries of the main companies in the sector and more than 2,500 companies meet at IFEMA (Madrid) from 9 to 11 October.

One of the novelties to be taken into account in this edition of the CPhI Worldwide will be the presentation of biological products by the bioLIVE platform, highlighting the recent growth of biological medicines.

BioLIVE, adjacent to CPhI Worldwide in 2018, is the exhibition and conference for large molecule biopharma needs. The event focuses specifically on manufacturing and processing and provides a unique platform connecting biotechs, big pharma and service providers across the value chain. The collaboration with CPhI Worldwide, brings together the small and large molecule worlds, creating a unique platform for both industries to learn from each other.

The arrival of this great event in Madrid comes at a particularly good time for the pharmaceutical industry in Spain, classified by global companies as one of the most internationally recognized, according to the Annual Report of CPhI, Global Pharma Index. This places Spain in the fourth place on the world scale (behind the United States, Germany and Japan and at the level of France and Italy) for the quality of its pharmaceutical production and the knowledge of its professionals. This study also points to Spain as the fastest-growing country worldwide in terms of innovation, for its ability to develop innovative manufacturing methods and new medicines.

NANBIOSIS has taken advantage of this incomparable framework to publicize its Cutting-Edge Biomedical Solutions and hold bilateral meetings with companies, including present collaborators such as Qualicaps (in the picture, Jesús Izco Executive Director of NANBIOSIS and Laura Canalejas together with Susana Ecenarro, Scientific Business Development Manager and Scientific Business Development Director of Qualicaps respectively)

Qualicaps supplies pharmaceutical-grade capsules together with a comprehensive service along the drug product life cycle through Qualicaps global team of commercial, scientific and technical experts. Originated in 1897 within Eli Lilly & Co. as a capsule manufacturing plant in the company’s headquarters in Indianapolis, USA. It is currently integrated into the Japanese group Mitsubishi Chemical Holdings Corporation.

• Read More

Nanoparticles characterization techniques of NANBIOSIS unit 6

The Unit 6 of NANBIOSIS, Biomaterial Processing and Nanostructuring Unit, has organized during the days 8 to 11 of October in the ICMAB-CSIC a course of characterization of Nanoparticles showing some of their techniques to the CSIC researchers.

Amable Bernabé, the technician of unit 6 of NANBIOSIS has shown the theory and practice of some methods to characterize nanoparticles and how to handle the necessary equipment.

Specifically, these techniques were:

Dynamic Light Scattering (DLS) with Zetasizer Nano ZS (Malvern Instruments)
- Size distribution
- Z Potential
Nanoparticle Tracking Analysis (NTA) with Nanosight NS300 (Malvern Instruments)
- Size distribution
- Particle concentration
- Fluorescence
Light Scattering (LS) with Mastersizer 2000 (Malvern Instruments)
- Size distribution

being these techniques developed through the equipment of unit 6 of NANBIOSIS among which are:

These techniques are part of the physical-chemical characterization of the cascade characterization service offered by NANBIOSIS and its diffusion will facilitate the access to the NANBIOIS ISCT increasing demand of NANBIOSIS unit 6.

• Read More

Researchers of NANBIOSIS U9 awarded for a work on scaffolds for dental regeneration

Researchers Manuel Arruebo and Víctor Sebastián, from the CIBER-BBN group led by Jesús Santamaría (NFP) at the University of Zaragoza, that coordinates NANBIOSIS Unit 9 Synthesis of Nanoparticles, have received the second prize of the Resomer Awards granted by the company Evonik, a international recognition to competitiviness.

Their work “Promoting bioengineered tooth innervation using nanostructured and hybrid scaffolds”, has been published in the journal Acta Biomaterialia 50 (2017) 493-501. In this work, the researchers of the CIBER-BBN manufactured biodegradable materials such as scaffolds to promote dental regeneration. These scaffolds contained an immunosuppressive drug that, in addition to avoiding rejection after implantation, favored innervation. These implants were evaluated in vitro and in vivo at the French National Institute for Medical Research in Strasbourg, in the group of Nadia Jessel, demonstrating in animal models that these implants favored tooth regeneration and that the regenerated teeth were vascularized and innervated, both necessary characteristics to obtain a good regeneration.

The company Evonik AG is one of the largest chemical companies in the world with more than 36,000 workers and chemical plants in more than 30 countries. Its specialty is fine chemistry and one of its flagship products are biodegradable polymers.

Article of reference

Promoting bioengineered tooth innervation using nanostructured and hybrid scaffolds. Kuchler-Bopp S, Larrea A, Petry L, Idoux-Gillet Y, Sebastian V, Ferrandon A, Schwinté P, Arruebo M, Benkirane-Jessel N. Acta Biomater. 2017 Mar 1;50:493-501. DOI: 10.1016/j.actbio.2017.01.001 Epub 2017 Jan 3.

• Read More

Ramón Martínez Máñez Master class on Nanomedicine at the Act of the Academic Opening year 2018-2019 of Spanish university

On September 25, the Polytechnic University of Valencia hosted the Solemn Act of the new Academic Opening year 2018-2019 of Spanish universities, coinciding with the commemoration of its 50th anniversary. This institutional act was chaired by S.M. King Felipe VI, the Minister of Science, Innovation and Universities, Pedro Duque, and the President of the Generalitat Valenciana, Ximo Puig, among many other authorities.

Ramón Martínez Máñez, has been in charge of teaching the master class of the new academic year. Ramón Martínez is professor of the Department of Chemistry of the UPV and director of the Interuniversity Research Institute of Molecular Recognition and Technological Development, besides Scientific Director of CIBER-BBN and Scientific Director of NANBIOSIS U26 NMR: Biomedical Applications II

In the master class, Martínez Máñez explained that nanomedicine aims to “identify diseases in their early stages at the cellular and molecular level through the use of nanodevices and contrast systems” in order to “provide an early diagnosis and, therefore, improve the prognosis of the disease“. Ramón Martínez Mañez, Rei Jaume I Award for New Technologies 2018 has underlined that, nanomedicine “is already a well-established area of knowledge that seeks to apply the continuous advances of nanotechnology to medicine” and that “there are numerous studies that demonstrate its great capacity for the development of new diagnostic devices, new systems for the controlled release of drugs and materials suitable for the development of tissues. In fact, as indicated “there are already in the market biomedical solutions based on nanotechnology such as nanoformulated drugs.” For the professor of the UPV, “we do not know what is the future of medicine, but without a doubt nanotechnology will play an important role in its development and, although we do not know who will carry out these advances, undoubtedly, the research developed in the university it will play a fundamental role “.

• Read More

NANBIOSIS participation in BioSpain 2018

NANBIOSIS participates in BioSpain 2018, which is taking place in this ninth edition, in Seville, on September 25-27. BioSpain is one of the main fairs of the European biotechnology sector. It is an event, organized by the Spanish Association of Biocompanies (ASEBIO) in collaboration with Andalusian government which aims to exchange knowledge, ideas and experiences among all actors in the biotechnology sector. In this edition BioSpain has gathered more than 1,500 attendees, 600 companies and 200 stands.
BioSpain is structured in a trade fair, a partnering system that facilitates these meetings, a conference program and an investor’s forum that brings together the most important investors in the world of life sciences (this year there are 25 attendees from seven countries such as Ysios Capital Partners, Andera Partner – former Edmond de Rothschild-, Biogeneration Ventures and Johnson & Johnson Innovation. In BioSpain counts with the presence 0f research centers and academics, pharmaceutical companies, investors, professional services and medical technology companies and supplies, apart from media.
The Executive Director of NANBIOSIS, Jesus Izco, has seized the opportunity offered by an event such as BioSpain, to hold various bilateral meetings with representatives of the industry and disseminate the new NANBIOSIS Cutting-Edge Biomedical Soluctions

• Read More

Nanoparticles in 3D printed bone prostheses that favor regeneration

The research group of Biomaterials for regenerative therapies of CIBER-BBN and IBEC, coordinator of Unit 5 of NANBIOSIS, Rapid Prototyping Unit, led by Elisabeth Engel, expert on nanoparticles and biomaterials, together with the company Avinent, expert in 3D printing, will develop new personalized solutions to improve treatments for bone diseases or injury.
So far, they have tested some bioactive nanoparticles based on calcium on the membrane of a chicken embryo and found that blood vessels formed in it and that the cartilage ossified forming a mature bone. The tests were carried out in mice and the result was also positive. The creators of this innovative product point out that, after three years, the prosthesis would have become a bone of its own. Although it could be applied in any part of the body, it seems that the first objective would be to test it in the maxillo-facial area. Experts estimate that more than a year may pass before human trials are conducted.

Source: Pronto Magazine, September 8, 2018

• Read More

Nanbiosis Contribution to biofilm development

NANBIOSIS Unit 17 Confocal Microscopy Service, has participated in the research results published by Science of the Total Environment in an article titled “Recycled desalination membranes as support material for biofilm development: A new approach for microcystin removal during water treatment”. The biofilm visualization has been performed by ICTS “NANBIOSIS”

For further information: doi.org/10.1016/j.scitotenv.2018.07.435

• Read More

CIBER-BBN Annual Conference 2018

CIBER-BBN will celebrate its 12th Annual Conference on November 12 and 13 in Vlladolid. In these conference there will be a session dedicated to NANBIOSIS. Likewise, the annual meeting of the Scientific Technical Advisory Committee of NANBIOSIS will take place.

As in previous occasions, the meeting will serve to know the activity of NANBIOSIS, the Singular Technical Scientific Infrastructure (ICTS) of the CIBER-BBN and the Minimally Invasive Surgery Center Jesus Usón for the production and characterization of biomaterials, nanomaterials and devices up to its preclinical validation. The new Cutting-edge Biomedical Solutions of NANBIOSIS wiil be presented.

• Read More

Prof. Jaume Veciana, Scientific Director of NANBIOSIS: Olivier Kahn Plenary Lecture speaker at the ICMM 2018

Prof. Jaume Veciana, Scientific Director of NANBIOSIS has been honored with the Olivier Kahn Plenary Lecture given at the 16th International Conference on Molecule-Based Magnets (ICMM 2018), held on September 1-5, 2018, in Rio de Janeiro, Brazil.

For further information: click here

• Read More

Label-free DNA-methylation detection by direct ds-DNA fragment screening using poly-purine hairpins

Prof Laura Lechuga, Scientific Director of NANBIOSIS Unit 4 Biodeposition and Biodetection Unit, has led the research whose results have been published by Biosensors and Bioelectronics with the title “Label-free DNA-methylation detection by direct ds-DNA fragment screening using poly-purine hairpins”

Cancer diagnosis continuously evolves due to the better understanding of tumorigenic processes. DNA-methylation is consolidated as an effective biomarker for cancer prognosis and diagnostic even in tumors of unknown origin. The reversibility of this epigenetic mechanism also places it as a high-profile tool for the development of more sophisticated and personalized therapies. Current methodologies, such as bisulfite conversion or PCR amplification, rely on complex procedures that make difficult the standardization of epigenetics analyses. Here we present an optical biosensor methodology based on Surface Plasmon Resonance that employs poly-purine reverse-Hoogsten hairpin probes capable of interacting directly with ds-DNA fragments by triple helix formation. The direct interaction with the material of interest can greatly enhance the reliability of the analysis providing a more accurate and precise diagnosis. We have demonstrated the capabilities of our methodology for the direct capture of ds-DNA fragments and specific methyl-cytosine quantification. Our poly-purine hairpin probe demonstrated the specific capture of ds-DNA fragments while the standard duplex-forming probes failed to do so. In addition, the biosensor methodology showed a strong correlation with the different DNA methylation status
between the sequences with a low signal variation (≤8%CV) along 35 hybridization/regeneration cycles. Through its straightforward procedure and versatility of detecting different DNA modifications related to the DNA methylation process, we anticipate that our strategy will enable a greater level of accuracy and precision in cancer diagnostics making a strong impact on the development of personalized therapies

• Read More

You are here : Home / News